Halozyme Therapeutics (HALO) Stock: Buy, Sell, or Hold?
HALO - Halozyme Therapeutics, Inc.
$124.83
0.46 (0.37%)
▲
5d:
+6.86%
30d:
+8.43%
90d:
+54.42%
WAIT
LOW Confidence
Analysis Updated: Oct 21, 2026 12:00 AM ET
Earnings: Nov 02, 2026
10d
Get Alerted When HALO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: HALO shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: HALO shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$157.90
Based on 12.4% avg growth
INTRINSIC VALUE TODAY
$98.04
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 8.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: HALO is currently trading at $124.83, which is considered extended relative to its 30-day fair value range of $107.85 to $118.31. From a valuation perspective, the stock is trading at a premium (Forward PE: 11.7) compared to its historical average (8.3). At these levels, the market is pricing in 12.0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, HALO is in a strong uptrend. The price is approaching resistance at $125.43. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: HALO scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. However, the stock is trading significantly above the average Wall Street target of $108.78. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, HALO is in a strong uptrend. The price is approaching resistance at $125.43. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: HALO scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. However, the stock is trading significantly above the average Wall Street target of $108.78. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$107.85 -
$118.31
Company Quality Score
40/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
13.3%
Protect Your Profits
HALO is technically overbought (RSI 74). Consider hedging now to protect against a potential pullback while keeping your upside.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range (+5.5% above its trading range)
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BEARISH: Trading 12.9% above Wall St target ($108.78)
- NEUTRAL: Trading at premium valuation - market expects 12.0% growth which is achievable
- WARNING: Composite score 40/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$107.85 -
$118.31
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$107.41
Resistance Level
$125.43
Current Trend
Strong Uptrend
Technical data as of
Oct 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
11.69
Wall Street Target
$108.78
(-12.9%)
Revenue Growth (YoY)
47.7%
Earnings Growth (YoY)
42.9%
Profit Margin
24.9%
Valuation Premium vs History
+12.0% premium
PE vs Historical
11.7 vs 8.3
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+12.0%
(market-implied from PE analysis)
1-Year Target
$139.81
(+12%)
2-Year Target
$156.59
(+25%)
3-Year Target
$175.38
(+41%)
3-Yr Target (if PE normalizes)
(PE: 12→8)
PE COMPRESSION
$124.52
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: 20.8%)
$374.18
(+200%)
Base:
(SPY PE: 11.7, Growth: 20.8%)
$220.24
(+76%)
Bear:
(PE: 8.3, Growth: 20.8%)
$156.38
(+25%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (36x PE), but valuation improves significantly next year (12x PE) as earnings recover.
Trailing PE: 35.84 | Current EPS (TTM): $3.47
Bull Case
$273.61
(+119%)
Analyst growth 100.0%, PE expands to 39.4
Base Case
$248.74
(+99%)
Market implied 100.0%, PE stable at 35.8
Bear Case
$84.57
(-32%)
Severe decline -20.0%, PE contracts to 30.5
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: October 22, 2026 6:29 AM ET
Data refreshes hourly during market hours. Next update: 7:29 AM
Data refreshes hourly during market hours. Next update: 7:29 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HALO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
28 analysts |
$92 | 72 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
23 analysts |
$108 | 70 BUY |
|
INCY
Incyte Corporation |
HOLD
28 analysts |
$130 | 76 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
22 analysts |
$283 | 51 HOLD |
|
SRRK
Scholar Rock Holding Corp |
STRONG BUY
18 analysts |
$70 | 69 BUY |
Advanced HALO Option Strategies
Professional options setups generated by AI based on today's HALO price and gamma walls.
